Russell Investments Group Ltd. cut its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 6.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 41,495 shares of the biotechnology company’s stock after selling 2,792 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.16% of Aclaris Therapeutics worth $1,126,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in ACRS. UBS Group AG boosted its stake in Aclaris Therapeutics by 60.4% in the 1st quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 1,681 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Aclaris Therapeutics by 269.0% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,801 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 3,500 shares during the period. Bank of Montreal Can boosted its stake in Aclaris Therapeutics by 1,793.1% in the 2nd quarter. Bank of Montreal Can now owns 7,137 shares of the biotechnology company’s stock worth $194,000 after purchasing an additional 6,760 shares during the period. Nationwide Fund Advisors boosted its stake in Aclaris Therapeutics by 8.3% in the 1st quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 510 shares during the period. Finally, Trexquant Investment LP bought a new position in Aclaris Therapeutics in the 1st quarter worth approximately $201,000. Institutional investors own 95.79% of the company’s stock.
In other news, Director Andrew N. Schiff purchased 108,601 shares of the stock in a transaction dated Wednesday, August 16th. The shares were purchased at an average cost of $23.02 per share, with a total value of $2,499,995.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 16.30% of the company’s stock.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) traded down 2.14% on Tuesday, reaching $26.02. The company’s stock had a trading volume of 84,158 shares. The company’s market capitalization is $695.67 million. Aclaris Therapeutics, Inc. has a 12-month low of $20.15 and a 12-month high of $33.25. The firm has a 50-day moving average of $26.61 and a 200 day moving average of $27.82.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.12. On average, equities research analysts anticipate that Aclaris Therapeutics, Inc. will post ($3.10) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2887000/russell-investments-group-ltd-sells-2792-shares-of-aclaris-therapeutics-inc-acrs.html.
Several research firms have weighed in on ACRS. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. ValuEngine upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Guggenheim restated a “buy” rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a research note on Tuesday, July 4th. Jefferies Group LLC restated a “buy” rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a research note on Wednesday, June 28th. Finally, Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $40.00.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.